Epitome Biosystems Launches Ti-Tyr™ Profiling Chips for Simultaneous Measurement of Multiple Cellular Events

Epitome Biosystems

Epitome Biosystems Launches Ti-Tyr™ Profiling Chips for Simultaneous Measurement of Multiple Cellular Events

August 7, 2007

Waltham, MA, August 7, 2007 – Epitome Biosystems announced today the commercial launch of its Ti-Tyr™ Phosphorylation Profiling Chip, providing researchers with substantially increased capabilities for measuring cellular activities in their drug discovery and development efforts. Ti-Tyr™ Chips enable specific, cell-based measurements of biological function to be made quickly and in a highly multiplexed format, increasing the amount of relevant data generated per sample. Ti-Tyr™ Chips incorporate Epitome’s proprietary EpiTag™ technology and are one in a series of products from Epitome providing valuable information on the underlying basis of disease and drug responses.

“All drugs trigger some form of cellular response across a network of signals,” said Neal Gordon, Ph.D., President, Epitome Biosystems. “By making simultaneous activity measurements across many cell targets, our products, such as the Ti-Tyr™ Profiling Chip, are paving the way for more informed decision making in drug development and in assessing patient treatment options. Powerful approaches for delivering comprehensive and biologically significant information about cell states are something the market has been demanding for a long time and will drive a paradigm shift in medical research.”

The Ti-Tyr™ Chip is an easy-to-use, high sample throughput approach for assessing cell activity states by profiling tyrosine phosphorylation. Cell activity is a highly regulated process and many diseases are caused by disruptions or alterations in cell signaling networks. Protein phosphorylation is a key mediator of cell activity changes and researchers are interested in accurately measuring phosphorylation to unveil how disease or drugs impact these cell networks. Ti-Tyr™ Chips measure quantitative phosphorylation changes with picomolar sensitivity, across a range of signaling pathways and cellular phenotypes. These measurements are an important foundation for drug discovery efforts focused on targeting kinases, particularly in oncology, diabetes and immune disorders.

First generation Ti-Tyr™ Profiling Chips are being offered as an early access product program beginning with sample analysis performed at Epitome with subsequent customized technology transfer for in-house use. Epitome will highlight the Ti-Tyr™ Chip at the 12th Annual Drug Discovery and Development Meeting in Boston, August 7 and 8th along with planned product expansion plans to include similar EpiTag™ Profiling Chips for threonine (Thr-Put™) and serine (Ser-Vey™) phosphorylation measurements. In addition, Epitome offers Q-SONAR™, a complementary mass spectrometry-based phosphorylation profiling discovery service. Q-SONAR™ delivers accurate and reproducible phosphorylation profiles – allowing researchers to see “the big picture” of network responses and allowing them to quickly focus on nodes or targets of interest.

About Epitome Biosystems

Epitome Biosystems is applying its protein measurement systems to increase the productivity of drug discovery and development and improve the understanding of patient variability and disease. The Company’s EpiTag? technology delivers highly specific, quantitative, multiplexed measurements of any protein or proteins in a user-friendly format. The Q-SONAR™ mass spectrometry-based biomarker discovery service generates quantitative phosphorylation profiles to elucidate cellular network responses. Epitome’s technology is validated, scaleable and can be applied broadly to assessing protein functional states or activities, including phosphorylation. For more information, visit www.epitomebiosystems.com.

Contact:

Neal F. Gordon, Ph.D.
President
Epitome Biosystems
(781) 891-3816
ngordon@epitomebiosystems.com